Inspec

Inspec FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Inspec (6656.T) as of Oct 21, 2026 is -747.14 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -322.81 % — a change of 131.45% (lower).

FCF Conversion

-747.14 %

YoY

131.45%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Inspec is 2026 -747.14 % . FCF Conversion Rate (FCF/EBITDA) of Inspec was 2025 -322.81 % . It decreases by 131.45% lower compared to the previous year.

The Inspec FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
197.23 JPY
Jan 1, 2020
-218.44 JPY
Jan 1, 2021
25.10 JPY
Jan 1, 2022
-305.99 JPY
Jan 1, 2023
-916.58 JPY
Jan 1, 2024
-5.49 JPY
Jan 1, 2025
-322.81 JPY
Jan 1, 2026
-747.14 JPY
The Inspec FCF Conversion history
YEARFCF ConversionYoY
-747.14 %+131.45%
-322.81 %+5,777.00%
-5.49 %-99.40%
-916.58 %+199.54%
-305.99 %-1,318.89%
25.10 %-111.49%
-218.44 %-210.75%
197.23 %+72.24%
114.51 %-53.98%
248.81 %-165.91%
-377.50 %+201.96%
-125.02 %-82.75%
-724.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inspec Stock analysis

What does Inspec do? inspec Inc. generates revenue through three primary segments. The Semiconductor Package Substrates and Precision Substrate Inspection Equipment segment sells appearance inspection equipment for semiconductor package substrates and precision printed circuit boards used in smartphones, tablets, PCs, and wearable terminals. The Precision Substrate Manufacturing Equipment segment provides photoplotters, inkjet printers, and direct imaging devices along with maintenance services for printed circuit boards. The Digital Pathology Related Equipment segment develops and sells medical image processing systems, specifically whole slide imaging (WSI) for digital pathology applications. Customers include manufacturers of advanced digital devices requiring semiconductor inspection, PCB producers needing photoplotters and imaging devices, and healthcare providers utilizing whole slide imaging systems for pathology diagnostics. The company's products target the semiconductor, electronics manufacturing, and medical imaging sectors with specific applications in device assembly, PCB production, and medical diagnostics. inspec Inc. focuses on equipment for semiconductor package substrates, precision substrates, and digital pathology, serving clients in the electronics and healthcare industries. The firm's inspection and imaging solutions are tailored to meet the quality control needs of high-tech manufacturing and medical diagnostics, with no mention of additional revenue streams beyond these three segments. Inspec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inspec stock

FCF Conversion Rate (FCF/EBITDA) of Inspec is -747.14 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Inspec changed from -322.81 % to -747.14 %, representing a 131.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Inspec since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Inspec with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Inspec

All Key Metrics — Inspec